Mifepristone Repurposing in Treatment of High-Grade Gliomas.

ABSTRACT: Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12-15 months and a 5-year overall survival of <5%. Although new strategies have been sought to enhance patient response, no significant increase in the global survival of glioma patients has been achieved. The option of developing new drugs implies a long and costly process, making drug repurposing a more practical alternative for improving glioma treatment. In the last few years, researchers seeking more effective cancer therapy have pursued the possibility of using anti-hormonal agents, such as mifeprist

SUBMITTER: Llaguno-Munive M 

PROVIDER: S-EPMC7930566 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature